Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03717844 · ClinicalTrials.gov registry record

Registry for Adults With Plasma Cell Disorders (PCD's)

A clinical trial of Multiple Myeloma and Amyloidosis, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
2,000
Enrollment target
1
Study location

NCT03717844: Recruiting study of Multiple Myeloma and Amyloidosis, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT03717844 is a study of Multiple Myeloma and Amyloidosis that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 2,000 participants, above the 542-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (269% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03717844, a study of Multiple Myeloma and Amyloidosis, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
2,000 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

Study Locations (1)

North Carolina

  • North Carolina Cancer Hospital - Chapel Hill

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2018-02-09
Est. Completion 2029-02

What NCT03717844 shows while recruiting

NCT03717844 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 542-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (269% higher).

The record links to 9 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.

NCT03717844 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03717844 about?

NCT03717844 is a clinical study titled "Registry for Adults With Plasma Cell Disorders (PCD's)". The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include...

What is the current status of trial NCT03717844?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2018-02-09. Estimated completion is 2029-02.

What conditions does trial NCT03717844 study?

This clinical trial studies the following conditions: Multiple Myeloma, Amyloidosis, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Light Chain Deposition Disease.

Who is sponsoring clinical trial NCT03717844?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03717844 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03717844's enrollment target sits among peer trials

2,000 12th of 438 higher than 426 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03717844, the US trial registry maintained by the National Library of Medicine. NCT03717844 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.